hD16F7-PBD

hD16F7-PBD is an antibody-drug conjugate (ADC) composed of the humanized monoclonal antibody hD16F7, which targets vascular endothelial growth factor receptor-1 (VEGFR-1), conjugated to a pyrrolobenzodiazepine (PBD) cytotoxic payload. VEGFR-1 is a tyrosine kinase receptor involved in pathological angiogenesis, tumor invasiveness, and the recruitment of protumoral M2 macrophages. A unique property of the hD16F7 antibody is its ability to preserve the decoy/anti-angiogenic function of soluble VEGFR-1, which sequesters VEGF-A and placental growth factor (PlGF) in the tumor microenvironment. hD16F7-PBD exerts potent cytotoxic effects on VEGFR-1-expressing tumor cells, such as melanoma and glioblastoma, as well as on components of the tumor microenvironment, including endothelial cells and M2-polarized macrophages. It is currently in preclinical development for the treatment of solid tumors.

Other names

hD16F7-pyrrolobenzodiazepinehD-16F7-pyrrolobenzodiazepinehD 16F7-pyrrolobenzodiazepine